TY - JOUR T1 - Adjuvant Therapy for Salivary Gland Carcinomas JF - Anticancer Research JO - Anticancer Res SP - 4165 LP - 4170 VL - 36 IS - 8 AU - MUTLAY SAYAN AU - PRASHANT VEMPATI AU - BRETT MILES AU - MARITA TENG AU - ERIC GENDEN AU - ELIZABETH G. DEMICCO AU - KRZYSZTOF MISIUKIEWICZ AU - MARSHALL POSNER AU - VISHAL GUPTA AU - RICHARD L. BAKST Y1 - 2016/08/01 UR - http://ar.iiarjournals.org/content/36/8/4165.abstract N2 - Aim: We compared the clinical outcomes and toxicity profile among a retrospective cohort of patients with primary major salivary gland carcinomas (SGCs) treated with surgery followed by adjuvant radiation therapy (S+RT) versus surgery and adjuvant chemoradiotherapy (S+CRT). Patients and Methods: Twenty patients (71%) underwent S+RT and eight (29%) S+CRT at our Institution between 2006 and 2015. Microscopic positive margins were present in 54% of the patients. Results: The 3-year overall survival (OS) was 100% with S+RT and 87.5% with S+CRT (p=0.141) and locoregional control (LRC) was 95% with S+RT and 87.5% with S+CRT (p=0.383). There were no significant differences in the rate of acute (p=0.801) and late (p=0.714) toxicities. Conclusion: While we await randomized data, adjuvant CRT may be considered as a viable therapeutic option for patients at high-risk of local or regional recurrence, especially in those with a positive microscopic margin where further surgery may result in functional cranial neuropathies. ER -